Pelthos Therapeutics Inc.
(NYSE Mkt: PTHS)
Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. It produces products under its proprietary nitic oxide-based technology platform "Nitricil". Its main product is a topical gel for the treatment of molluscum contagiosum. The company was founded on March 19, 2021 and is headquartered in Durham, NC.
25.780 -
+1.090
(+4.41%)
Range
24.610 - 25.780
(4.75%)
Open
25.450
Previous Close
24.690
Bid Price
10.310
Bid Volume
200
Ask Price
29.300
Ask Volume
100
Volume
5,620
Value
46,350
Remark
-
Delayed prices. Updated at 30 Jan 2026 05:15.
Data powered by
View All Events
Loading Chart...
Please login to view stock data and analysis
